Dr. Bunn on Targeting HER3 in NSCLC

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted TherapiesПодробнее

Dr. Bunn on Treating Advanced-Stage Lung Cancer with TKIsПодробнее

Rational for HER3-targeting in NRG1 fusion-positive NSCLCПодробнее

Dr. Bunn on Combining Immunotherapy and Chemotherapy in Lung CancerПодробнее

Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and OthersПодробнее

Dr. Bunn Discusses Afatinib in Lung CancerПодробнее

Dr. Bunn Discusses the Need to Study Drug Combinations in Lung CancerПодробнее

Dr. Bunn on TMB as a Biomarker in Small Cell Lung CancerПодробнее

Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLCПодробнее

Necitumumab: Targeting EGFR with next-generation antibodies - Paul BunnПодробнее

Lung Cancer Treatment: How Do Targeted Therapies Work?Подробнее

Dr. Bunn on Immunotherapy Advances in Small Cell Lung CancerПодробнее

Dr. Bunn Discusses the Potential Benefit for a Blood-Based Test to Detect a T790M MutationПодробнее

The Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLCПодробнее

Lung Cancer Update | 2022 Metro Denver Oncology Nursing Society ConferenceПодробнее

Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community SettingПодробнее

Immunotherapy in Lung CancerПодробнее

Dr. Bunn on Missed Endpoint in CheckMate-026 for NSCLCПодробнее

Dr. Bunn on the MYSTIC Trial for Lung CancerПодробнее